



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 54690

Title: Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use:
A case report

Reviewer's code: 03004570

Position: Editorial Board

Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: Japan

Manuscript submission date: 2020-02-14

Reviewer chosen by: Xiao-Quan Yu

Reviewer accepted review: 2020-05-19 12:51

Reviewer performed review: 2020-05-26 14:32

Review time: 7 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This manuscript is an informative case report about the pneumothorax after bevacizumab use. There are 4 figures of chest CT which are perfect. As the authors indicated, this severe side effect is due to bronchopleural fistula. The incidence of serious fistulae is between <1% and 1.8% and the majority of them occurs within 6 months of first dose (reference: Bevacizumab FDA pdf). In this case, the occurrence of pneumothorax is before cycle 3, day 1, this should be approximately 4 weeks after the first dose of bevacizumab. The authors should mention the doses and schedules of Bevacizumab + Paclitaxel regimen for correct information. I recommend also correction of some minor typing errors; for ex. "Case Presentation" in place of Case Presentstion (in pp#6), "severe" in place of sever (in pp#9), "bronchopleural" in place of bronchi-pleural (in pp# 4 & 8).